سعر لوربرينا 25 مجم 30 قرص 2026

Lorbrena 25 mg by Pfizer (Egypt): lorlatinib film-coated tablets, an ALK/ROS1 kinase inhibitor for ALK-positive metastatic non-small cell lung cancer.

• Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive as detected by an approved test.Population: AdultsPfizer (labeling.pfizer.com)

• Most frequent adverse reactions (20% or more) in Study B7461001: oedema, peripheral neuropathy, cognitive effects, dyspnoea, fatigue, weight gain, arthralgia, mood effects and diarrhoea; frequent laboratory abnormalities include hypercholesterolaemia, hypertriglyceridaemia, anaemia, hyperglycaemia and increased AST, ALT, lipase and alkaline phosphatase.Egyptian label · Pfizer (labeling.pfizer.com)
• Serious adverse reactions occurred in 32% of 295 patients (most often pneumonia, dyspnoea, pyrexia, mental status changes and respiratory failure); fatal adverse reactions occurred in 2.7%.Egyptian label · Pfizer (labeling.pfizer.com)

• Contraindicated in patients taking strong CYP3A inducers, due to the potential for serious hepatotoxicity.Egyptian label · Pfizer (labeling.pfizer.com)

• Serious hepatotoxicity with strong CYP3A inducers: discontinue strong CYP3A inducers for 3 plasma half-lives before starting lorlatinib.Egyptian label · Pfizer (labeling.pfizer.com)
• Central nervous system effects (seizures, psychotic effects, changes in cognition, mood including suicidal ideation, speech, mental status and sleep) occurred in 52% of 476 patients; withhold, reduce the dose or discontinue according to severity.Egyptian label · Pfizer (labeling.pfizer.com)
• Hyperlipidaemia: grade 3-4 elevations of cholesterol (18%) and triglycerides (19%); initiate or increase lipid-lowering therapy.Egyptian label · Pfizer (labeling.pfizer.com)

• Strong CYP3A inducersContraindicated (risk of serious hepatotoxicity and reduced lorlatinib exposure).Pfizer (labeling.pfizer.com)
• Moderate CYP3A inducersAvoid; if unavoidable, increase the lorlatinib dose to 125 mg once daily.Pfizer (labeling.pfizer.com)
• Strong CYP3A inhibitors; fluconazoleAvoid; if unavoidable, reduce the starting dose from 100 mg to 75 mg once daily (from 75 mg to 50 mg if already reduced for adverse reactions, for strong inhibitors).Pfizer (labeling.pfizer.com)

• Based on animal studies and its mechanism of action, lorlatinib can cause embryo-fetal harm; there are no data in pregnant women. In rats and rabbits it caused malformations, post-implantation loss and abortion at exposures equal to or below human exposure at 100 mg daily.Egyptian label · Pfizer (labeling.pfizer.com)
• No data on presence in human or animal milk; because of the potential for serious adverse reactions in breastfed infants, women should not breastfeed during treatment and for 7 days after the final dose.Egyptian label · Pfizer (labeling.pfizer.com)

• Lorlatinib: Kinase inhibitor with in vitro activity against ALK and ROS1 (and TYK1, FER, FPS, TRKA-C, FAK, FAK2, ACK), including multiple mutant ALK forms detected at progression on other ALK inhibitors; active in intracranial tumour models.

Store at 20-25 C; excursions permitted between 15 and 30 C.